Ozen M, Hopwood V L, Balbay M D, Johnston D A, Babaian R J, Logothetis C J, von Eschenbach A C, Pathak S
Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Int J Oncol. 2000 Jul;17(1):113-7. doi: 10.3892/ijo.17.1.113.
The purpose of this research was to correlate non-random chromosomal aberrations in the peripheral blood lymphocytes (PBLs) of prostate cancer patients with specific clinical parameters. Peripheral blood samples were analyzed from 59 informative prostate cancer patients. Non-random chromosomal alterations detected in the PBLs and their correlation with any specific clinical parameters were analyzed statistically. A comparison was made between specific chromosomal abnormalities in the patients having an early (<65 years) or late (> or =65 years) age at disease onset, low-grade (Gleason grade <7) or high-grade (Gleason grade > or =7) tumors, a low (<10 ng/ml) or high (> or =10 ng/ml) prostate-specific antigen (PSA) level, and androgen-sensitive or -insensitive disease. In examining the specific chromosomal breakpoints, the regions 1p13, 2q21, 3p21, 4q13, 5q31, 6p21, 7p15, 7p13, 7q32, 10p11, 10q26, 11p15, 11p11, 14q12, and 16q12 showed breaks in at least four cases. Chromosome 15 (P=0. 045) was significantly altered in patients having a PSA value greater than or equal to 10, while it (P=0.017) and chromosome 19 (P=0.036) were significantly altered in patients having a PSA value greater than or equal to 20. In addition, chromosomes 5 (P=0.032), 8 (P=0.020), 16 (P=0.009), and 20 (P=0.047) were significantly altered in patients having a Gleason grade greater than 7. Also, chromosomes 2 (P=0.020) and 3 (P=0.044) were significantly altered in patients who had early disease onset. Additionally, chromosome 10 (P=0.041) was significantly altered in patients having metastasis, and chromosomes 4 (P=0.006) and 7 (P=0.028) were significantly altered in patients having androgen-insensitive disease. In spite of the small subset of patients, chromosome 8 (p=0.003) was significantly altered in patients having small cell carcinoma of the prostate. From these results we conclude that non-random chromosomal aberrations present in PBLs of prostate cancer patients can be correlated with specific clinical parameters. These correlations can be used to identify a prostate cancer patient's risk response to therapy.
本研究的目的是将前列腺癌患者外周血淋巴细胞（PBL）中的非随机染色体畸变与特定临床参数相关联。分析了59例信息丰富的前列腺癌患者的外周血样本。对PBL中检测到的非随机染色体改变及其与任何特定临床参数的相关性进行了统计分析。对疾病发病年龄早（<65岁）或晚（≥65岁）、低级别（Gleason分级<7）或高级别（Gleason分级≥7）肿瘤、低（<10 ng/ml）或高（≥10 ng/ml）前列腺特异性抗原（PSA）水平以及雄激素敏感或不敏感疾病的患者的特定染色体异常进行了比较。在检查特定染色体断点时，1p13、2q21、3p21、4q13、5q31、6p21、7p15、7p13、7q32、10p11、10q26、11p15、11p11、14q12和16q12区域在至少4例中出现断点。PSA值大于或等于10的患者中，染色体15（P=0.045）有显著改变，而PSA值大于或等于20的患者中，染色体15（P=0.017）和染色体19（P=0.036）有显著改变。此外，Gleason分级大于7的患者中，染色体5（P=0.032）、8（P=0.020）、16（P=0.009）和20（P=0.047）有显著改变。疾病发病早的患者中，染色体2（P=0.020）和3（P=0.044）有显著改变。此外，有转移的患者中，染色体10（P=0.041）有显著改变，雄激素不敏感疾病的患者中，染色体4（P=0.006）和7（P=0.028）有显著改变。尽管患者子集较小，但前列腺小细胞癌患者中，染色体8（p=0.003）有显著改变。从这些结果我们得出结论，前列腺癌患者PBL中存在的非随机染色体畸变可与特定临床参数相关联。这些相关性可用于识别前列腺癌患者对治疗的风险反应。
